Sunil Agarwal, PhD
Interventional Cardiology · Springfield, ILNPI 1710204334
Payments from drug & device makers
Across 264 payments — averaging $2305.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Janssen Research & Development, LLC$555K
- Boehringer Ingelheim International GmbH$18K
- Biogen$13K
- Boehringer Ingelheim Pharma GmbH & Co.kg$12K
- Boston Scientific$5K
- Medtronic$2K
- plus $4K from 19 others
Across 12 payments — averaging $135.44 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boehringer Ingelheim International GmbH$2K
What the payments were for
- Consulting fees$18,03076%
- Travel & lodging$1,9718%
- Food & beverage$3,86916%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Janssen Research & Development, LLC | 46 | $555,435 |
| Boehringer Ingelheim International GmbH | 40 | $17,649 |
| Biogen | 1 | $12,500 |
| Boehringer Ingelheim Pharma GmbH & Co.kg | 3 | $11,685 |
| Boston Scientific | 8 | $5,487 |
| Medtronic(2 entities) | 21 | $2,220 |
| Abbott | 14 | $1,074 |
| Edwards Lifesciences | 4 | $708 |
| Novartis | 90 | $645 |
| Abiomed | 6 | $557 |
| AstraZeneca | 5 | $144 |
| Averitas Pharma Inc. | 1 | $114 |
| Johnson & Johnson | 6 | $100 |
| Amgen | 4 | $74 |
| Pfizer | 3 | $61 |
| Boehringer Ingelheim | 2 | $41 |
| Alnylam Pharmaceuticals Inc. | 1 | $23 |
| Irhythm Technologies, Inc. | 1 | $21 |
| Merck | 1 | $20 |
| Shockwave Medical, Inc | 1 | $17 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $16 |
| Esperion Therapeutics, Inc. | 1 | $16 |
| Novo Nordisk | 1 | $14 |
| Amarin Pharma, Inc. | 1 | $14 |
| SPR Therapeutics, Inc | 1 | $3 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GENERAL - THERAPIES$5,105
- COREVALVE EVOLUT R$1,315
- PROCLAIM$641
- Edwards SAPIEN 3 Transcatheter Heart Valve$530
- Impella$273
- VANTA ADAPTIVESTIM$173
- OCTRODE$156
- WATCHMAN Access System$130
- GENERAL PAIN MANAGEMENT$116
- Qutenza$114
How this compares
$608,639 in reported general payments places this provider in the 95th percentile of 303 interventional cardiology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 1,174 | $1,154,267 |
| XareltoRivaroxaban | 197 | $230,167 |
| EntrestoSacubitril/Valsartan | 203 | $206,506 |
| JardianceEmpagliflozin | 131 | $125,330 |
| Praluent PenAlirocumab | 89 | $117,459 |
| Repatha SureclickEvolocumab | 92 | $108,330 |
| BrilintaTicagrelor | 37 | $34,831 |
| FarxigaDapagliflozin Propanediol | 34 | $34,058 |
| Metoprolol Succinate | 1,952 | $20,715 |
| Diltiazem 12hr ErDiltiazem Hcl | 123 | $10,969 |
| Atorvastatin Calcium | 1,156 | $9,619 |
| Ranolazine ErRanolazine | 80 | $8,535 |
| Amlodipine Besylate | 1,284 | $8,395 |
| Rosuvastatin Calcium | 866 | $8,185 |
| ClopidogrelClopidogrel Bisulfate | 738 | $7,277 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $61 | $1,154,2671,174 claims |
| Johnson & JohnsonXarelto | $100 | $230,167197 claims |
| NovartisEntresto | $645 | $206,506203 claims |
| Boehringer IngelheimJardiance | $41 | $125,330131 claims |
| AstraZenecaBrilinta, Farxiga | $144 | $68,88971 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 303 interventional cardiology providers in Illinois.
Other interventional cardiology in Springfield
- Krishna Rocha SinghSpringfield$1.7M
- Avinash MurthySpringfield$553K
- Donald YakelSpringfield$503K
- John GillSpringfield$372K
- Tony de MartiniSpringfield$208K
- Shady HenienSpringfield$105K
- Salem BadrSpringfield$94K
- Charles DavidsonChicago$5.8M
- Ravi RamanaPalos Park$2.8M
- Mark RicciardiEvanston$2.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.